A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer
Clinical trial NCT05681728 · UNKNOWN
Trial details
- NCT number
- NCT05681728
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-01
- Primary completion
- 2024-02-01
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.